About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 418 record(s)
Req # A-2021-000981
All drafts and/or final copies of inspection reports into Ovo Fertilité / Clinique Ovo / Ovo Clinic, based in Montreal, Quebec., including any follow up inspections, recommendations and corrective actions requested against the clinic between January 1, 2020 to September 23, 2021.Organization: Health Canada
June 2022
Req # A-2021-001077
All records on data breaches related to the COVID-19 Alert app. Descriptions of the number, type and date of data breaches that have occurred for the COVID-19 Alert mobile app. Date range January 2020 to August 5, 2021.Organization: Health Canada
June 2022
Req # A-2021-001704
All information included in the submission and review of Natural Product Number (NPN) 80046464.Organization: Health Canada
June 2022
Req # A-2021-001707
The full Health Canada Product Licence Application (PLA) for the product listed below, including information such as the Class, Application type as well as the monographs used to apply for the below product. Natural Product Number (NPN): 80036830. Brand name(s): Peppermint Halo. Licence holder: Saje Natural Business Inc.Organization: Health Canada
June 2022
Req # A-2021-001815
All communications between anyone at the Public Health Agency of Canada (PHAC) and anyone at the Office of the Privacy Commissioner concerning PHAC’s acquisition of the mobiliy of Canadians from Telus. The dates covered by this request are 1 January 2020 to 11 January 2022.Organization: Health Canada
June 2022
Req # A-2021-001829
All communications sent/received by ministry officials at the Director General (DG), Assistant Deputy Minister (ADM) or Deputy Minister (DM) level regarding or discussing the issues with the COVID Alert App mentioned in this news story: https://globalnews.ca/news/8478550/attempts-improve-covid-alert-stall-lack-of-interest-provinces/ . Records from December 1, 2021 to January 24, 2022.Organization: Health Canada
June 2022
Req # A-2021-001850
Ministerial briefing notes prepared for Carolyn Bennett, minister of mental health and addictions, for a meeting sometime between January 19 2022 - February 1 2022 concerning the substance use emergency declaration called in the Yukon.Organization: Health Canada
June 2022
Req # A-2021-001949
All documents held by Health Canada regarding Risk Assessments reports, Test Reports, Inspection Reports, and Cosmetic Notification which include the terms : "tattoo", "tattoo ink" or "tattoo printer ink", combined with at least one of these terms: "organic solvents”, "solvents", "heavy metals", "pigments", "lithium", "cadmium", "lead". Date range is from year 1990 until January 1st, 2000.Organization: Health Canada
June 2022
Req # A-2021-002114
The screening acceptance letter(s) from Health Canada to any and all generic drug manufacturer(s) for any and all abbreviated new drug submissions (ANDS) for the following medicinal ingredients which appear on the list of Generic Drug Submissions under review dated March 15, 2022: atorvastatin, levetiracetam, ticagrelor.Organization: Health Canada
June 2022
Req # A-2022-000078
The Module 1.3.1 Note to reviewer indicating the brand name of the reference drug product and the dosage form of the generic drug in the list of generic drug submissions under review for the medicinal ingredient Gabapentin. The Screening Acceptance Letter from Health Canada to any and all generic drug manufacturers confirming completion of screening of any and all Abbreviated New Drug Submissions for gabapentin which appear on the list of Generic Drug Submissions Under Review (GSUR).Organization: Health Canada
June 2022